WASHINGTON: Canada’s system of setting drug prices helps control rising prescription costs, but its reach is limited and it may impede drug development, a congressional report said Feb.22. The report by the General Accounting Office comes as committees in Congress and the Clinton administration are looking at the U.S. pricing practices of pharmaceutical companies.
Article extracted from this publication >> February 26, 1993
